Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

Journal of Experimental Medicine

Volumn 172, Issue 4, 1990, Pages 1217-1224

  Gansbacher, Bernd ^a   Zier, Karen ^b   Daniels, Brian ^a   Cronin, Kathy ^a   Bannerji, Rajat ^a   Gilboa, Eli ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CELL CULTURE; GENE TRANSFER; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMAL; CYTOTOXICITY, IMMUNOLOGIC; HUMAN; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0025000864     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.172.4.1217     Document Type: Article

References (37)

1. Foley, E.J. 1953. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13: 835.
2. Prehn, T.R., and J.M. Main. 1957. Immunity to methyl-cholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18: 769.
3. Old, L.J., E.A. Boyse, D.A. Clarke, and E.A. Carswell. 1962. Antigenic properties of chemically induced tumors. Ann. NY Acad. Sci. 101: 80.
4. Hewitt, H.B., E.R. Blake, and A.S. Walder. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br. J. Cancer. 33: 241.
5. Key, M.E., J.S. Brandhorst, and M.G. Hanna, Jr., 1984. More on the relevance of animal tumor models: immunogenicity of transplantable leukemias of recent origin in syngeneic strain 2 guinea pigs. J. Biol. Response Modif. 3: 359.
6. Forni, G., and A. Santoni. 1984. Immunogenicity of "nonim-munogenic" tumors. J. Biol. Response Modif. 3: 128.
7. Shu, S., T. Chou, and K. Sakai. 1989. Lymphocytes generated by in vivo priming and in vivo sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J. Immunol. 143: 740.
8. Kamo, I., and H. Friedman. 1977. Immunosuppression and the role of suppressive factors in cancer. Adv. Cancer Res. 25: 271.
9. Naor, D. 1979. Suppressor cells: permitters and promoters of malignancy? Adv. Cancer Res. 29: 45.
10. North, R.J. 1985. Down-regulation of the antitumor immune response. Adv. Cancer Res. 45: 1.
11. Erard, F., P. Corthesy, M. Nabholz, J.W. Lowenthal, P. Zaech, G. Plaetinck, and H.R. MacDonald. 1985. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J. Immunol. 134: 1644.
12. Mosmann, T.R., and R.L. Coffman. 1987. Two types of mouse helper T-cell clone. Immunol. Today. 8: 223.
13. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187.
14. Rosenberg, S.A., and M.T. Lotze. 1986. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 4: 681.
15. Cheever, M.A., P.D. Greenberg, A. Fefer, S. Gillis. 1982. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J. Exp Med. 155: 968.
16. Chou, T., S. Bertera, A.E. Chang, and S. Shu. 1988. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol. 141: 1775.
17. Donohue, J.H., M. Rosenstein, A.E. Chang, M.T. Lotze, R.J. Robb, and S.A. Rosenberg. 1984. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J. Immunol. 132: 2123.
18. Cameron, R.B., P.J. Spiess, and S.A. Rosenberg. 1990. Syner- gistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. J. Exp Med. 171: 249.
19. DeLeo, A.B., H. Shiku, T. Takahashi, M. John, and L.J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and al-loantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp Med. 146: 720.
20. Srivastava, P.K., A.B. DeLeo, and L.J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA. 83: 3407.
21. Cullen, B.R. 1988. Expression of a cloned human interleukin-2 cDNA is enhanced by the substitution of a heterologous mRNA leader region. DNA (NY). 7: 645.
22. McKnight, S. L. 1980. The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acid Res. 8: 5949.
23. Wano, Y, B.R. Cullen, P.A. Svetlik, N.J. Pfeffer, and W.C. Greene. 1987. Reconstitution of high affinity IL-2 receptor expression in a human T-cell line using a retroviral cDNA expression vector. Mcl. Biol. Med. 4: 95.
24. Armentano, D., S.-F. Yu, P.W. Kantoff, T. von Ruden, W.F. Anderson, and E. Gilboa. 1987. Effect of internal viral sequences on the utility of retroviral vectors. J. Virol 61: 1647.
25. Hantzopoulos, P.A., B.A. Sullenger, G. Ungers, and E. Gilboa. 1989. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc. Natl. Acad. Sci. USA. 86: 3519.
26. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids.J. Virol. 62: 1120.
27. Markowitz, D., S. Goff, and A. Bank. 1988. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 167: 400.
28. Zier, K. 1982. Functional and antigenic properties of cultured T-cells in the cell mediated lympholysis (CML) assay. Hum. Immunol. 4: 147.
29. Smith, K.A., M.F. Favata, and S. Oroszla. 1983. Production and characterization of monoclonal antibodies to human interleukin 2. Strategy and tactics. J. Immunol. 131: 1808.
30. Takei, F., J.G. Levy, and D.G. Kilburn. 1976. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.). Immunol. 116: 288.
31. Takei, F., J.G. Levy, and D.G. Kilburn. 1977. Characterization of suppressor cells in mice bearing syngeneic mastocytoma. J. Immunol. 118: 412.
32. Thompson, J.A., D.J. Peace, J.P. Klarnet, DE. Kern, P.D. Greenberg, and M. A. Cheever. 1986. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J. Immunol. 137: 3675.
33. Rosenberg, S.A., J.J. Mule, P.J. Spiess, CM. Reichert, and S.L. Schwarz. 1985. Regression of established pulmonary metastases and subcutaneous tumors mediated by the systemic administration of high dose recombinant Interleukin 2. J. Exp Med. 161: 1169.
34. Forni, G., H. Fujiwara, F. Martino, T. Hamaoka, C. Jemma, P. Caretto, and M. Giovarelli. 1988. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev. 7: 289.
35. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57: 503.
36. Watanabe, Y, K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata. 1989. Exogenous expression of mouse interferon-gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl Acad. Sci. USA. 86: 9456.
37. Fearon, E.R., D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60: 397.